Increased Risk for Cervical Disease Progression of French Women Infected with the Human Papillomavirus Type 16 E6-350G Variant
- Martha Grodzki1,
- Guillaume Besson2,
- Christine Clavel2,
- Annie Arslan3,
- Silvia Franceschi3,
- Philippe Birembaut2,
- Massimo Tommasino3 and
- Ingeborg Zehbe4
- 1Johannes Gutenberg University, Medical Microbiology, Mainz, Germany; 2Laboratoire Pol Bouin, Hopital Maison Blanche, CHU, Reims, France; 3IARC, Lyon, France; and 4Thunder Bay Regional Health Sciences Centre, Regional Cancer Care, Thunder Bay, Ontario, Canada
- Requests for reprints:
Ingeborg Zehbe, Thunder Bay Regional Health Sciences Centre, Regional Cancer Care Programme, 980 Oliver Road, Thunder Bay, Ontario P7B 6V4, Canada. Phone: 807-684-7256; Fax: 807-684-5806. E-mail: zehbei{at}tbh.net
Abstract
To test the significance of human papillomavirus (HPV) type 16 and HPV16 E6 variants as risk factors for viral persistence and progression to high-grade lesion, we did a nested case-control study within a cohort study of >15,000 Caucasian French women. Three groups infected with high-risk HPV were compared: (a) women with cleared infection (controls, n = 201), (b) women with persistent infection (cases, n = 87), and (c) women who progressed into high-grade lesion (cases, n = 58). Women with persistent HPV infection and those that progressed into high-grade lesions were likelier to harbor HPV16 than other high-risk HPV types [odds ratio (OR), 2.4; 95% confidence interval (95% CI), 1.3-4.3 and OR, 4.2; 95% CI, 2.2-8.1, respectively]. Notably, especially elevated ORs of persistence (3.0; 95% CI, 1.4-6.7) and progression (6.2; 95% CI, 2.7-14.3) were found among women who harbored the HPV16 350G variant. Thus, HPV type and HPV16 variant seem to be risk factors for viral persistence and progression of infections into high-grade cervical lesions. Cancer Epidemiol Biomarkers Prev 2006:15(4);820–2
Footnotes
-
↵5 Besson et al., in preparation.
-
Grant support: Deutsche Krebshilfe, Bonn, Germany grant 70-3050-Ze (I. Zehbe); La Ligue Contre le Cancer (M. Tommasino); and Comité du Rhône et Comité de la Drôme, France (M. Tommasino).
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
Note: This work has been done in fulfillment of the requirements for the M.D. thesis of M. Grodzki.
-
M. Grodzki and G. Birembaut contributed equally to this work.
-
- Accepted February 2, 2006.
- Received November 8, 2005.
- Revision received January 6, 2006.
